Available evidence does not suggest a link between the use of GLP-1 receptor agonists, including Ozempic and Wegovy, and suicidal thoughts or actions, according to a review from drug regulators in Europe.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
